Form 4: Iteos Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director David Hallal acquired stock options for Iteos Therapeutics, Inc. on June 11, 2024.
Summary
- On June 11, 2024, David Hallal, a director of Iteos Therapeutics, Inc., acquired stock options.
- The stock options grant the right to buy 24,200 shares of common stock at an exercise price of $16.32.
- The options become exercisable on June 11, 2025, and expire on June 11, 2034.
- Following the transaction, Hallal directly owns 24,200 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a standard disclosure of stock option grants to a company director, a common practice in the biotech industry to incentivize and align the director's interests with those of the shareholders.
Stakeholder Impact
- The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to make decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of stock option acquisition |
| 06/11/2025 | Stock options become exercisable |
| 06/11/2034 | Stock options expiration date |
| 06/13/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.